Kalaris Therapeutics, Inc.

NasdaqGM:KLRS Stock Report

Market Cap: US$97.2m

Kalaris Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Andrew Oxtoby

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage20.93%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure1.5yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Seeking Alpha • Dec 18

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Summary Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS’s lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26. KLRS stock's valuation is driven by TH103’s clinical potential, with an enterprise value of ~$119M and significant upside tied to trial catalysts. Read the full article on Seeking Alpha
Analysis Article • Nov 20

Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 23

We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Andrew Oxtoby's remuneration changed compared to Kalaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$44m

Dec 31 2025US$3mUS$538k

-US$43m

Sep 30 2025n/an/a

-US$55m

Jun 30 2025n/an/a

-US$82m

Mar 31 2025n/an/a

-US$76m

Dec 31 2024US$2mUS$394k

-US$69m

Compensation vs Market: Andrew's total compensation ($USD2.57M) is above average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Oxtoby (52 yo)

2.3yrs
Tenure
US$2,569,115
Compensation

Mr. Andrew Oxtoby serves as Director at Aravax Pty Ltd since April 2026. He serves as President and Chief Executive Officer at Kalaris Therapeutics, Inc. from March 4, 2024. He is Director at Kalaris Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Oxtoby
President2.3yrsUS$2.57mno data
Srinivas Akkaraju
Director & Co-Founderno dataUS$140.43k0%
$ 0
Michael Dybbs
Co-Founder & Directorno dataUS$143.43k0%
$ 0
Napoleone Ferrara
Independent Director & Co-Founderno dataUS$151.09k2.12%
$ 2.1m
Brett Hagen
Chief Accounting Officer and Principal Accounting & Financial Officer1.3yrsUS$1.44m0%
$ 0
Matthew Feinsod
Chief Medical Officer1.5yrsUS$1.67m0.017%
$ 16.5k
Kristine Curtiss
Senior Vice President of Clinical1.4yrsno datano data
Jill Porter
Senior Vice President of CMCno datano datano data
1.5yrs
Average Tenure
54yo
Average Age

Experienced Management: KLRS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Andrew Oxtoby
President2.3yrsUS$2.57mno data
Srinivas Akkaraju
Director & Co-Founder6.8yrsUS$140.43k0%
$ 0
Michael Dybbs
Co-Founder & Director4.3yrsUS$143.43k0%
$ 0
Napoleone Ferrara
Independent Director & Co-Founder6.8yrsUS$151.09k2.12%
$ 2.1m
Anthony Adamis
Independent Director4.6yrsUS$141.91k0%
$ 0
Leone Patterson
Independent Director1.2yrsUS$145.68k0%
$ 0
David Hallal
Independent Chairman of the Board7.8yrsUS$244.43k0.55%
$ 533.3k
Morana Jovan-Embiricos
Independent Director7.1yrsUS$156.31k0.91%
$ 881.3k
5.7yrs
Average Tenure
59.5yo
Average Age

Experienced Board: KLRS's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 19:45
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kalaris Therapeutics, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniil GataulinChardan Capital Markets, LLC
Jonathan WollebenCitizens JMP Securities, LLC
Marc GoodmanLeerink Partners LLC